← Back to Calendar
Live Company Data
NYQ
Updated
4m ago
· Data: FMP
Current Price
$193.88
+31.37%
+$46.30 today
Day: $192.61 – $194.64
52-Week Range
Current price is at 79% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
HR+/HER2- advanced breast cancer — first-line (frontline, traditional design)
Key Notes
SERENA-4 Phase 3 readout expected H2 2026 (Fierce Pharma). Traditional first-line design: camizestrant + Pfizer Ibrance (palbociclib) vs standard endocrine therapy + CDK4/6i in frontline HR+/HER2- advanced breast cancer. Distinct from SERENA-6 (the emergent ESR1 mutation "switch" design that supports the NDA under ODAC review April 30). If both SERENA-6 and SERENA-4 succeed, camizestrant could displace aromatase inhibitors as the dominant endocrine backbone for HR+ breast cancer.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.